Table 8.
Nrf2-related therapeutic effects of curcumin in cancers.
| Type of Disease | Type of Curcumin | Animals | Dose Range | Cell Line | Targets and Other Pathways |
Function | Ref. |
|---|---|---|---|---|---|---|---|
| Ovarian Carcinoma (OC) |
CUR | Female Wistar rat |
100 mg/kg, orally, daily, 4 weeks |
SKOV3 | ETBR, ET-1, Caspase-3/9, Bax, Bcl-2, N-cadherin, E-cadherin, Vimentin | CUR via the Nrf2/ETBR/ET-1 axis could prevent EMT-mediated OC progression. | [77] |
| Lymphoblastoma | CUR | - | - | CL-45 | p53, Caspase-3/9, PARP, HMOX1 | CUR during oxidative stress-induced apoptosis could induce p53-independent inactivation of Nrf2. | [80] |
| Prostate Cancer (PCa) | F10, E10 |
- | - | TRAMP-C1, HepG2-C8 |
ARE, HO-1, UGT1A1, NQO1, HDAC7,H3, DNMT3a, DNMT3b | Curcumin derivatives could reactivate Nrf2 in TRAMP C1 cells. | [81] |
| Colorectal Cancer (CRC) |
CUR | - | - | HCT-8/5-Fu, HCT-8 | NQO1, Bcl-2, Bax | CUR via the Nrf2 could affect multidrug resistance (MDR) in human CRC. | [78] |
| Breast Cancer (BC) |
CUR | - | - | MCF-7 | Fen1, AKR1B10, AKR1C1/3 | CUR via Nrf2-mediated down-regulation of Fen1 could inhibit the proliferation of BC cells. | [79] |